

# A REVIEW ON PULSATILE DRUG DELIVERY SYSTEM

<sup>1</sup>Rahath Bushra, <sup>2</sup>Dr.Shahid Mohammed, <sup>3</sup>Dr.A.Shajudha Begum

<sup>1</sup>M.Pharmacy, <sup>2</sup>Professor, <sup>3</sup>Assistant professor  
Department of Pharmaceutics,  
Deccan School of Pharmacy, Hyderabad, Telangana, India.

**Abstract:** Traditionally, drugs are release in an immediate or extended fashion. However, in recent years, pulsatile drug release systems are increasing developing interest. This framework is designed for chronopharmacotherapy which is based on circadian rhythm. The rationale for the employment of pulsatile release is for the drugs where a constant drug release, i.e., a zero-order release is not desired. Pulsatile drug delivery system (PDDS) is defined as the rapid and transient release of certain amount of molecules within a short time period immediately after a predetermined off-release period, i.e., lag time. PDDS can be classified into time controlled systems wherein the dug release is controlled primarily by the delivery system; stimuli induced PDDS in which release is controlled by the stimuli, like the pH or enzymes present in the intestinal tract or enzymes present in the drug delivery system and externally regulated system where release is programmed by external stimuli like magnetism, ultrasound, electrical effect and irradiation. Therefore, Pulsatile drug delivery is one such system that, by delivering drug at the right time, right place and in right amount, holds good promises of benefit to the patients suffering from chronic problems like arthritis, asthma, peptic ulcer, cardiovascular diseases, and hypercholesterolemia. Current review article focuses on the necessity of pulsatile drug delivery systems, types of the disease in which pulsatile release is required, classification, evaluations, advantages, limitation, and future aspects of pulsatile drug delivery system.

**Keywords:** Pulsatile drug release, Chronopharmacotherapy, Circadian rhythm, Lag time, Time controlled systems.

## I. INTRODUCTION

Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound within the body as required to safely achieve its desired therapeutic effect <sup>[1]</sup>. Drug delivery is of two types:

### 1. Conventional


- Oral/Enteral
- Buccal
- Rectal
- Parenteral

### 2. Modified

- Delayed Release
- Sustained Drug Delivery
- Extended Release
- Site specific targeting
- Pulsatile <sup>[1]</sup>

## PULSATILE DRUG DELIVERY SYSTEM

Pulsatile drug delivery is defined as the rapid and transient release of certain amount of active molecules within a short time period immediately after a predetermined off released period, i.e., lag time, or these systems have a peculiar mechanism of delivering the drug rapidly and completely after a lag time, i.e., a period of no drug release. Such a release pattern is known as pulsatile release <sup>[2]</sup>. Pulsatile drug delivery systems (PDDS) have attracted attraction because of their multiple benefits over conventional dosage forms. They deliver the drug at the right time, at the right site of action and in the right amount that provides more benefit than conventional dosages and increased patient compliance. These systems are designed according to the circadian rhythm of the body, and the drug is released rapidly and completely as a pulse after a lag time. These products follow the sigmoid release profile characterised by a time period. These systems are beneficial for drugs with chronopharmacological behavior, where nocturnal dosing is needed, and for drugs that show the first-pass effect <sup>[2]</sup>.



**Fig.1: Drug release profiles from pulsatile drug delivery system.**

Where, **A:** Conventional release profile, **B:** Burst release of drug as a after a lag time, **C:** Delayed release profile after a lag time, **D:** Constant release profile in prolonged period after a lag time, **E:** Extended release profile without lag time.

### NECESSITY OF PULSATILE DRUG DELIVERY SYSTEMS

There are many conditions and diseases where sustained release formulations don't show good efficiency. In such cases Pulsatile Drug Delivery System is applicable.

- 1. First pass metabolism** Some drugs, like beta blockers, and salicylamide, undergo extensive first pass metabolism and require fast drug input to saturate metabolizing enzymes in order to minimize pre-systemic metabolism. Thus, a constant/sustained oral method of delivery would result in reduced oral bioavailability.
- 2. Biological tolerance** Continuous release drug plasma profiles are often accompanied by a decline in the pharmacotherapeutic effect of the drug, e.g., biological tolerance of transdermal nitroglycerin.
- 3. Special chronopharmacological needs** Circadian rhythms in certain physiological functions are well established. It has been recognized that many symptoms and onset of disease occur during specific time periods of the 24 hour day, e.g., asthma and angina pectoris attacks are most frequently in the morning hours.
- 4. Local therapeutic need** For the treatment of local disorders such as inflammatory bowel disease, the delivery of compounds to the site of inflammation with no loss.

### ADVANTAGES

- Predictable, reproducible and short gastric residence time.
- Less inter- and intra-subject variability.
- Improves bioavailability.
- Reduced adverse effects and improved tolerability.
- Limited risk of local irritation.
- No risk of dose dumping.
- Flexibility in design.
- Ease of combining pellets with different compositions or release patterns
- Improves stability.
- Improves patient comfort and compliance.
- Achieves a unique release pattern<sup>[3]</sup>.

### LIMITATIONS

Pulsatile drug delivery systems have certain limitation, so in many cases these drug delivery system is fails,

- Multiple manufacturing steps in case of Multiparticulate pulsatile drug delivery system.
- Low drug load
- Incomplete release
- In-vivo variability in single unit pulsatile drug delivery system.

**Table 1: Diseases that require pulsatile drug delivery<sup>[2]</sup>.**


Diseases	Chronological behavior	Drugs used
Peptic ulcer	Acid secretion is high in the evening and at night.	H2 blockers <sup>[4]</sup>
Cancer	The blood flow to tumors is 3-fold greater during each daily activity phase of the circadian cycle than during the daily rest phase.	Vinca alkaloids, Taxanes <sup>[5]</sup>

Duodenal ulcer	Gastric acid secretion is highest at night while gastric and small bowel motility and gastric emptying are all slower at night.	Proton pump inhibitors <sup>[6]</sup>
Neurological disorders	The central pathophysiology of epilepsy and the behavioral classification of convulsive events	MAO-B inhibitor <sup>[7]</sup>
Hypercholesterolemia	Cholesterol synthesis is generally higher during night than day time.	HMG CoA reductase Inhibitors <sup>[8]</sup>
Diabetes mellitus	Increase in the blood sugar level after meal	Sulfonylurea, Insulin <sup>[9]</sup>
Cardiovascular diseases	BP is at its most minimal during the sleep cycle and rises steeply during the early morning	Nitroglycerin, calcium channel blocker, ACE inhibitors <sup>[10]</sup>
Asthma	Precipitation of attacks during night or at early morning.	B2 agonist, Antihistamines <sup>[11]</sup>

**Chrono-therapeutics** refers to a therapy in which In vivo availability of drug is timed to match rhythms of disease or disorders in order to improve therapeutic responses and minimize side effects, which makes it a profound and purposeful delivery of medications in unequal amounts over time (during the 24 h). Chronotherapeutics takes into account rhythm determinants of the human circadian time structure to determine the drug-delivery pattern, dose, and administration time to optimize desired and/or minimize adverse effects.

#### BIOLOGICAL RHYTHMS:

- 1. Ultradian Rhythms:** Oscillations of shorter span are termed Ultradian Rhythms (more than one cycle per 24 h). E.g.90 minutes sleep cycle.
- 2. Infradian Rhythms:** Oscillations that are longer than 24 hours are named as Infradian Rhythms (less than one cycle per 24hours). E.g. Monthly Menstruation.
- 3. Circadian rhythms:** Circadian rhythms are self-sustaining, endogenous oscillations that occur with a periodicity of about 24 Hours and regulate many body functions like-metabolism, sleep pattern, hormone production etc. Several physiological processes in humans vary in a rhythmic manner, in synchrony with the internal biological clock <sup>[12]</sup>.



**Fig.2:Diseases displaying circadian rhythm**

## II. CLASSIFICATION OF PULSATILE DRUG DELIVERY SYSTEM

### Various approaches of pulsatile drug:

Pulsatile drug delivery system can be broadly classified into three classes;

1. Time controlled pulsatile drug delivery
2. Stimuli induced pulsatile drug delivery
3. Externally regulated pulsatile drug delivery


#### 1. Time controlled pulsatile drug delivery

- A. Single unit pulsatile systems
  1. Capsule based systems E.g. Pulisincap system
  2. Capsular system based on Osmosis
    - a. 'PORT' System
    - b. System based on expandable orifice

- c. Delivery by series of stops.
  - d. Pulsatile delivery by solubility modulation
  3. Pulsatile system with Erodible or soluble barrier coatings.
    - a. The chronotropic system
    - b. 'TIME CLOCK' System.
    - c. Compressed tablets
    - d. Multilayered Tablets
  4. Pulsatile system with rupturable coating
- B. Multiparticulate / Multiple unit systems:
1. Pulsatile system with rupturable coating E.g. Time –controlled Explosion system (TCES)
  2. Osmotic based rupturable coating system E.g. Permeability controlled system
  3. Pulsatile delivery by change in membrane permeability E.g. Sigmoidal release system.

### A. Single unit pulsatile systems

**1. Capsule based systems:** Single-unit systems are mostly developed in capsule form. The lag time is controlled by a plug, that gets pushed away by swelling or erosion, and therefore the drug is released as a "Pulse" from the insoluble capsule body. <sup>[13]</sup> The lag time can be controlled by manipulating the dimension and therefore the position of the plug. <sup>[14,15]</sup>



**Fig.3: Design of Pulsincap system** <sup>[25]</sup>


Polymers used for designing of the hydrogel plug are as follows:

- Insoluble but permeable and swellable polymers (e.g., polymethacrylates)
- Erodible compressed polymers (e.g., hydroxypropylmethyl cellulose, polyvinyl alcohol, Polyethylene oxide)
- Congealed melted polymers (e.g., saturated polyglycolated glycerides, glyceryl monooleate)
- Enzymatically controlled erodible polymer (e.g., pectin) The lag time can be controlled by manipulating the dimension and the position of the plug <sup>[16]</sup>.

### 2. Capsular system based on Osmosis

#### a. 'PORT' System <sup>[17]</sup>

The Port system fig. (2) was developed by Therapeutic system research laboratory Ann Arbor, Michigan, USA, and consists of a capsule coated with a semipermeable membrane. Inside the capsule was an insoluble comprising of osmotically active agent and the drug formulation. <sup>[31]</sup> When this capsule interacted with the dissolution fluid, the semipermeable membrane allowed the entry of water, which caused the pressure to develop and the insoluble plug expelled after a lag time. Such a system was utilized to deliver methylphenidate utilized in the treatment of attention deficit hyperactivity disorder as the pulsatile port system. This system avoided second time dosing, which was beneficial for school children during daytime.



**Fig.4: Drug release mechanism from PORT system**

**b. System based on expandable orifice:** To deliver the drug in liquid form, an osmotically driven capsular system was developed within which the liquid drug is absorbed into extremely porous particles, that release the drug through an orifice of a semipermeable capsule upheld by an expanding osmotic layer once the barrier layer is dissolved. <sup>[18]</sup>




Fig. 5: System based on expandable orifice [32]

The orifice is small enough in order that once the elastic wall relaxes, the flow of the drug through the orifice basically stops, however once the elastic wall is distended beyond threshold value, the orifice expands sufficiently to permit drug release at a required rate. E.g. Elastomers, such as styrenebutadiene copolymer are recommended. [19,20]

**c. Delivery by series of stops:** This system is described for implantable capsules. The capsule contains a drug and a water absorptive osmotic engine that are placed in compartments separated by a movable partition. The pulsatile delivery is achieved by a series of stops on the inner wall of the capsule. These stops obstruct the movement of the partition but are overcome in succession because the osmotic pressure rises above a threshold level. [21]

**d. Pulsatile delivery by solubility modulation:** Such systems contain a solubility modulator for pulsed delivery of variety of drugs. The system was especially developed for delivery of salbutamol sulphate. [22-24] The compositions contains the drug (salbutamol sulfate) and a modulating agent (sodium chloride). The amount of NaCl was such that it was less than the amount needed to maintain saturation in a fluid that enters the osmotic device. The pulsed delivery is based on drug solubility. Salbutamol has solubility of 275mg/ml in water and 16 mg/ml in saturated solution of NaCl, whereas NaCl has solubility of 321 mg/ml in water, and its saturation solubility is 320 mg/ml.

**3. Pulsatile system with Erodible or soluble barrier coatings:** Most of the pulsatile drug delivery systems are reservoir devices coated with a barrier layer. This barrier erodes or dissolves after a specific lag period, and the drug is subsequently released quickly from reservoir core. The lag time depends on the thickness of the coating layer.

**a. The chronotropic system:**

The Chronotropic® system consists of a drug-containing core coated by hydrophilic swellable hydroxypropylmethyl cellulose (HPMC), that is responsible for a lag phase in the onset of release. [25-27] Additionally, through the application of an outer gastric-resistant enteric film, the variability in gastric emptying time can be overcome, and a colon-specific release can be obtained, relying on the relative reproducibility of small intestinal transit time. [28] The lag time is controlled by the thickness and the viscosity grades of HPMC. [29] Both in-vitro and in vivo lag times correlate well with the applied amount of the hydrophilic retardin polymer. The system is suitable for both tablets and capsules. [30]




Fig. 6: The chronotropic system [25-27]

**b. 'TIME CLOCK' System:** [22-27]

The lag time could be controlled by varying the thickness of the film. After the lag time, i.e., the time required for rehydration, the core immediately releases the drug. This system has shown reproducible results in vitro and in vivo. The effect of low calorie and high calorie meal on the lag time was studied using gamma scintigraphy. The mean lag time of drug release was 345 and 333 min respectively. [29-30]



Fig.7: 'TIME CLOCK' System [39-44]


**c. Compressed Tablets:** Compression coating can involve direct compression of both the core and the coat, obviating needs for separate coating process and use of coating solutions. The outer tablet of the compression-coated tablet provides the initial dose, rapidly disintegrating in the stomach and the inner layer is formulated with components that are insoluble in gastric media but are released in the intestinal environment. [31] Materials such as hydrophilic cellulose derivatives can be used. Compression is easy on

laboratory scale. The major drawbacks of the technique are that relatively large amounts of coating materials are needed and it is difficult to position the cores correctly. [31]

Press-coated pulsatile drug delivery systems:

1. Press-coated pulsatile drug delivery systems can be used to protect hygroscopic, light-sensitive, oxygen-labile or acid-labile drugs.
2. Press-coated pulsatile drug delivery systems are relatively simple and cheap.
3. These systems can involve direct compression of both the core and the coat.
4. Materials such as hydrophobic, hydrophilic can be used in press-coated pulsatile drug delivery system.
5. Press-coated pulsatile drug delivery systems involve compression which is easy on laboratory scale.
6. Press-coated pulsatile formulations release drug after "lag-time".
7. Press-coated pulsatile drug delivery formulations can be used to separate incompatible drugs from each other or to achieve sustained release.

**d. Multilayered Tablets:** A release pattern with two pulses was obtained from a three-layered tablet containing two drug-containing layers separated by a drug-free gellable polymeric barrier layer. [32-34]




**Fig.8: Multilayered Tablet** [46-48]

**4. Pulsatile system with rupturable coating:** These systems rely upon the disintegration of the coating for the discharge of drug. The pressure necessary for the rupture of the coating is achieved by the effervescent excipients, swelling agents, or osmotic pressure. An effervescent mixture of citric acid and sodium bicarbonate was incorporated in a tablet core coated with ethyl cellulose. The carbon dioxide developed after penetration of water into the core resulted in a pulsatile release of drug after rupture of the coating. [35] The release could rely upon the mechanical properties of the coating layer. [35]

**B. Multiparticulate / Multiple unit systems:**

**a) Pulsatile system based on rupturable coating:** [35-38]

E.g. Time-controlled Explosion system (TCES): This is a multiparticulate system in which drug is coated on non-pareil sugar seeds followed by a swellable layer and an insoluble top layer. [50-52] The swelling agents used include Superdisintegrants like sodium carboxymethyl cellulose, sodium starch glycolate, L hydroxypropyl cellulose. Polymers like polyvinyl acetate, polyacrylic acid, polyethylene glycol, etc.



**Fig.9: Time-controlled Explosion system (TCES)** [35-38]

**b) Osmotic based rupturable coating system:** This technique is based on a combination of osmotic and swelling effects. The core containing the drug, a low bulk density solid and/or liquid lipid material (eg, mineral oil) and a disintegrant was prepared. This core was then coated with cellulose acetate. Upon immersion in aqueous medium, water penetrates the core displacing lipid material. When the depletion of lipid material, internal pressure will increase till a critical stress is reached, which results in rupture of coating. [39]

**c) Pulsatile delivery by change in membrane permeability:** The permeability and water uptake of acrylic polymers with quaternary ammonium groups is influenced by the presence of different counter-ions within the medium. [40] Several delivery systems based on this ion exchange are developed. Eudragit RS 30D is reported to be a polymer of choice for this purpose. It usually contains positively polarized quaternary ammonium group in the polymer side chain, which is always accompanied by negative hydrochloride counter-ions. The ammonium group being hydrophilic facilitates the interaction of polymer with water, thereby changing its permeability and allowing water to permeate the active core in a controlled manner. This property is essential to achieve a precisely defined lag time. [41]

## 2. Stimuli induced pulsatile drug delivery

1. Temperature-induced pulsatile release
2. Chemical stimuli-induced pulsatile release:
  - Glucose-responsive insulin release devices
  - Inflammation-induced pulsatile release
  - Drug release from intelligent gels responding to antibody concentration.
  - Electric stimuli-responsive pulsatile release

**1. Temperature-induced pulsatile release:** Thermoresponsive hydrogels are investigated as possible drug delivery carriers for stimuli responsive drug delivery systems. [42-44] Poly (Nisopropylacrylamide) (PIPAAm) cross-linked gels have shown

thermoresponsive, discontinuous swelling / deswelling phases: swelling, for example, at temperatures below 328°C, while shrinking above this temperature. Thermo-responsive polymeric micelle systems as Kataoka et al. [45] comprehensively reviewed, the properties and biological interests of polymeric micelles create them a most noteworthy candidate as drug carrier for the treatment of cancer. The polymeric micelle is composed of amphiphilic block copolymers exhibiting a hydrophobic core with a hydrophilic corona. The application of a temperature gradient induced an on-off drug release regulation from PIPAAm PBMA micelles between 4 and 378 °C.

## 2. Chemical stimuli-induced pulsatile release

**a) Glucose-responsive insulin release devices :** A decrease in or the absence of insulin secretion from pancreatic islets is the cause of diabetes mellitus. Diabetes mellitus patients suffer long run from a gradual decline within the potency of various organs, like the occasional loss of eyesight. Many systems have already been developed which are able to respond to glucose concentration changes. Glucose oxidase (GOD) catalyzes glucose oxidation. Utilizing this reaction, Ishihara et al. [46] prepared two types of gel membrane systems to control insulin permeability. They prepared and nicotinamide-immobilized gel membranes, separately.

**b) Inflammation-induced pulsatile release** When human beings receive physical or chemical stress, like injury, broken bones, etc., inflammation reactions take place at the injured sites. At the inflammatory sites, inflammation-responsive phagocytic cells, like macrophages and polymorphonuclear cells, play a role in the healing process of the injury. During inflammation, hydroxyl radicals (OH) are produced from these inflammation-responsive cells. Yui and co-workers [47-48] used hyaluronic acid (HA), a linear mucopolysaccharide composed of repeating disaccharide subunits of N-acetyl-D-glucosamine and D-guluronic acid. Within the body, HA is especially degraded either by a specific enzyme, hyaluronidase, or hydroxyl radicals. Degradation of HA via the hyaluronidase is very low in a normal state of health. Degradation via hydroxyl radicals however, is usually dominant and fast once HA is injected at inflammatory sites. Thus, Yui and associates [47-48] prepared cross-linked HA with ethyleneglycol diglycidylether or polyglycerol polyglycidylether. These HA gels degraded only when the hydroxyl radicals were generated through the Fenton reaction between Fe<sup>+2</sup> ions and hydrogen peroxide in vitro. Thus, a surface erosion type of degradation was achieved. When microspheres were incorporated within the HA hydrogels as a model drug, these microspheres were discharged only when hydroxyl radicals induced HA gel degradation. The microsphere release was regulated by the surface erosion type of degradation.

**c) Drug release from intelligent gels responding to antibody concentration:** There are numerous kinds of bioactive compounds that exist within the body. Recently, novel gels were developed that responded to the change in concentration of bioactive compounds to alter their swelling/deswelling characteristics. Miyata and associates focused on the introduction of stimuli responsive cross-linking structures into hydrogels. Special attention was given to antigen antibody complex formation as the cross-linking units in the gel, because specific antigen recognition of an antibody can provide the basis for a new device fabrication.

**d) Electric stimuli-responsive pulsatile release:** The combination of developments in several technologies, like microelectronics and micromachining, as well as the potential need for chronotherapy, have currently assisted the development of electronically assisted drug delivery technologies. These technologies include iontophoresis, infusion pumps, and sonophoresis [49]. Several approaches have also been presented in the literature describing the preparation of electric stimuli-responsive drug delivery systems using hydrogels. Kishi et al. [50] developed an electric stimuli induced drug release system using the electrically stimulated swelling /deswelling characteristics of polyelectrolyte hydrogels. They used a chemomechanical system, that contained a drug model within the polyelectrolyte gel structure. These gels exhibited reversible swelling / shrinking behavior in response to on-off switching of an electric stimulus. Thus, drug molecules within the polyelectrolyte gels might be squeezed out from the electric stimuli-induced gel contraction along with the solvent flow. To realize this mechanism, poly (sodium acrylate) microparticulate gels containing pilocarpine as a model drug were prepared.[51]

**3. Externally regulated pulsatile drug delivery:** For releasing the drug in a pulsatile manner, another way can be the externally regulated systems in which drug release is programmed by external stimuli like magnetism, ultrasound, electrical effect and irradiation. Magnetically regulated systems contain magnetic beads within the implant. On application of the magnetic field, drug release occurs because of magnetic beads. Saslawski et al. [52] developed different formulation for in vitro magnetically triggered delivery of insulin based on alginate spheres. In case of ultrasonically modulated systems, ultrasonic waves cause the erosion of the polymeric matrix thereby modulating drug release. Miyazaki et al [53] evaluated the effect of ultrasound (1 MHz) on the discharge rates of bovine insulin from ethylenevinyl alcohol copolymer matrices and reservoir-type drug delivery systems during which they found sharp drop in blood glucose levels after application of ultrasonic waves. Additionally irradiation with light rays the desired drug release pattern. Mathiowitz et al [54] developed photochemically controlled delivery systems prepared by interfacial polymerization of polyamide microcapsules. For this purpose, azobisisobutyronitrile (AIBN), a substance that photochemically emanates nitrogen gas, was incorporated. Because of exposure of azobisisobutyronitrile to light, causing release of nitrogen and an increase in the pressure which ruptures the capsules thereby releasing the drug.

## RECENT ADVANCES IN THE PULSATILE DRUG DELIVERY [55-56]

Nowadays pulsatile drug delivery systems are gaining importance in numerous disease conditions specifically in diabetes wherever dose is needed at different time intervals. Among these systems, multi-particulate systems (e.g. pellets) offer numerous benefits over single unit that include no risk of dose dumping, flexibility of blending units with different release patterns, as well as short and reproducible gastric residence time. Multiparticulate systems consists pellets of various release profile which might be of any type like time dependent, pH dependent, micro flora activated system as discussed in the previous sections. Site and time specific oral drug delivery have recently been of great interest in pharmaceutical field to attain improved therapeutic efficacy. Gastroretentive drug delivery system is an approach to prolong gastric residence time, thereby targeting sitespecific drug release in upper gastrointestinal (GI) tract. Floating drug delivery system (FDDS) and bioadhesive drug delivery are widely used techniques for gastro retention. Low density porous multiparticulate systems are employed by researchers for formulation of FDDS. Sharma and Pawar developed multiparticulate floating pulsatile drug delivery system using porous calcium silicate and sodium alginate for

time and site specific drug release of meloxicam. Various pulsatile technologies have been developed on the basis of methodologies as discussed previously. These includes OROS® technology, CODAS® technology, CEFORM® technology, DIFFUCAPS® technology, Threedimensional printing®, timerx® etc.

**Table 2: Marketed Products of Pulsatile Drug Delivery**

Technology	API	Disease	Proprietary name
CODAS®	Verapamil Hcl	Hypertension	Verelan® PM
CONTIN®	Theophylline	Asthma	Uniphyl®
CEFORM®	Diltiazem HCl	Hypertension	Cardiazem®
Diffucaps®	Verapamil HCl, Propranolol HCl	Hypertension	Innopran®
Pulsincap®	Metronidazole	Antihelminthic	-
Geoclock™	Prednisone	Rheumatoid arthritis	Lodotra
OROS®	Methylphenidate	Anti-psychotic	Concerta®
PULSYS™	Amoxicillin	Antibiotic	Moxtag™
Three dimensional printing®	Diclofenac sodium.	Inflammation	Theiform®
TIMERx®	Oxymorphone	Pain management	OPANA®

### III. EVALUATION TEST OF PULSATILE DRUG DELIVERY SYSTEM:

**Preformulation study:**<sup>[57]</sup> Different physicochemical properties of drug and drug in excipient mass are evaluated in Preformulation study.

**Drug excipients interaction study:**<sup>[58]</sup> The Fourier transform infrared (FTIR) technique and Differential scanning calorimetry (DSC) can be used to study the physical and chemical interactions between the drug and excipients used.

**Evaluation of granule:**<sup>[57]</sup> Prepared granules are evaluated for Angle of Repose, Bulk Density, Tapped Density, Carrs index (or) % Compressibility, Hausner's Ratio.

**Tablet Thickness:**<sup>[57]</sup> Thickness of tablet is measured using vernier caliper. Five tablets are selected randomly from individual formulations and thickness is measured using vernier caliper scale. The test is carried out in triplicate.

**Uniformity of weight:**<sup>[57]</sup> Twenty tablets are taken and their weight is determined individually and collectively on a digital weighing balance. The average weight of one tablet is determined from the collective weight. Not more than two tablets deviate from the percentage given below from the average weight and none deviate by more than twice the percentage shown. The Pharmacopoeial Specification of weight variation is given in following table 4:

**Table 3: Weight Uniformity Criteria for tablet**

S.No.	Average weight of tablets(mg)	Percentage deviation
1	80mg or less	±10
2	More than 80mg but less than 250mg	±7.5
3	250mg or more	±5

**Hardness/ Crushing strength:**<sup>[57]</sup> Hardness or tablet crushing strength (fc the force required to break a tablet in a diametric compression) is measured using Monsanto Hardness tester. It is expressed in Kg/cm<sup>2</sup>. Tablets require certain amount of strength or hardness and resistance to friability, to withstand mechanical shocks of handling in manufacture, packaging, and shipping.

**Evaluation of polymeric film (only in film coating approach):**<sup>[58]</sup>

**a) Visual evaluation:** Casted films are visually evaluated for Physical properties of film like could be peeled off easily from the plate or not; Appearance of the film formed like smooth-rough surface, oily-non oily, Transparent-Opaque film.

**b) Tensile strength:** The casted films after drying are carefully cut into film strips (length 40 mm x width 20 mm) and investigated for tensile strength. The method used for evaluating the mechanical properties is based on guideline. Tensile strength = Breaking Force ( F ) / Cross sectional area ( A )

**c) Folding endurance:** The test is carried out to check the efficiency of the plasticizer and strength of the film prepared using varying concentration of the plasticizers. The folding endurance is measured manually. A strip of film (2 x 2 cm) is cut evenly and repeatedly folded at the same place until it breaks. The number of times counted until film could be folded at the same place without breaking, this is gave the value of folding endurance. The test is carried out in triplicate.

**d) Mechanical properties:** Polymer films (6.5 X 6.7 cm<sup>2</sup>) are fixed in a self-designed Teflon holder <sup>[59,60]</sup> with several holes (diameter 10 mm). Films are fixed using the holder and optionally immersed into 0.1 N HCl at 37 C for 2 h (wet films). The mechanical properties of the dry and wet films are measured with a puncture test using a Texture analyzer (n = 3). A metal probe with a hemispherical end (diameter 5 mm, length 15 cm) is driven at a speed of 5 mm/min until the film ruptured force– displacement curves are recorded and following parameters are calculated:



Puncture strength =  $F_{max} / ACS$

Where,  $F_{max}$  is the maximum applied force at film break, ACS is the cross-sectional area of the edge of the film located in the path of the cylindrical hole of the film holder, with  $ACS = 2rd$  where  $r$  is the radius of the hole in the holder and  $d$  is the thickness of the film.

**In vitro dissolution study:**<sup>[61]</sup> The in vitro dissolution study is performed using dissolution test given in monograph or in standard literature. In general case, dissolution media are 900 ml of 0.1 M HCl for 2 h (since average gastric emptying time is 2 h) and 900 ml of phosphate buffer pH 6.8 for 3 h (average small intestinal transit time). After 5 h, the dissolution medium is replaced with pH 7.4 phosphate buffer (900 ml) and tested for the drug release up to specific hour dissolution study. At the predetermined time intervals, specific volume of dissolution media (1, 2, 5, 10 ml etc..) are withdrawn, filtered through a 0.45  $\mu$ m membrane filter, diluted, and assayed at wavelength maxima using a UV spectrophotometer.

**Comparison of dissolution profiles:**<sup>[61]</sup> The similarity factor ( $f_2$ ) given by SUPAC guidelines for a modified release dosage form is used as a basis to compare dissolution profiles. The dissolution profiles are considered to be similar when  $f_2$  is between 50 and 100. The dissolution profiles of products are compared using  $f_2$  which is calculated from the following formula: Where,  $n$  is the dissolution time and  $R_t$  and  $T_t$  are the reference) and test dissolution value at time  $t$ .

**Kinetic modeling of dissolution data:**<sup>[61]</sup> The dissolution profile of all batches are fitted to various models such as zero order, first order, Higuchi, Hixon Crowell, Korsmeyer and Peppas to ascertain the kinetic of drug release.

**In vivo study of prepared formulation:**<sup>[61]</sup> The prepared formulation is tested for an in vivo study to check the passage of the dosage form throughout the GIT. The purpose of the in vivo study is to find the location of the capsule during its passage through the GI tract. In this study, drug granules are replaced with barium sulfate. The dosage form is prepared in the similar manner as optimized formulation. The volunteer with overnight fasting is taken for the study. The laxative is given to the volunteer before 12 h of the study to completely empty the GIT content. The X-ray study is performed at 2-h, 3-h, 5-h, and 8-h interval.

**Pharmacokinetic parameters comparison:**<sup>[62]</sup> Different pharmacokinetic parameters like  $C_{max}$  ( $\mu$ g/ml),  $t_{max}$  (h), AUC (ng.h/ml),  $K_{el}$  (h<sup>-1</sup>) and  $t_{1/2}$  (h) are compare for optimized formulation and marketed tablet.

**Anti-inflammatory activity study:**<sup>[63]</sup> Male albino rats, weighing (150 – 180 g), are used for this study; they are housed in four groups, each of 5 rats, and are allowed free access to food and water prior to the experiments.

Group I: Control untreated, received 1% carrageenan only.

Group II: Treated 1% carrageenan injection+ Optimized formulation after 2 hr.

Acute inflammation is induced in rats by the injection of 1% carrageenan solution sub-cutaneously into the sub-plantar regions of the left hind paw of rats. The thickness of the injected paw is measured immediately after carrageenan injection and after 1, 2, 3 and 4 hours using a micrometer. The mean percentage inhibition of edema thickness at each time interval is calculated from the mean increase in thickness in control and treated animals according to the equation:

Percentage inhibition in edema thickness =  $[1 - (T_t/T_c)] \times 100$  (Eq. 9)

Where  $T_t$  and  $T_c$  are the mean increase in thickness of the carrageenan injected paw of the drug treated and control group respectively. The significant inhibition of inflammation indicates effectiveness of drug substance.

**Dissolution–ex vivo permeation study using everted rat intestine:**<sup>[64,65]</sup> Intestine is isolated from a male Wistar rat. A median incision is made into the abdomen, the small intestine is freed, and the lumen is carefully cleared with a Krebs-Ringer solution. The intestinal segment is everted and the distal 5 cm part is used. One end of the isolated everted intestinal segment is fixed to a straight cannula and at the other end tied using a thread to a 1 g weight. The system is filled with Krebs-Ringer solution and is completely immersed into the dissolution vessel of the dissolution test apparatus containing 900 mL of suitable dissolution fluid. During the study, assemblies are maintained at  $37 \pm 0.5^\circ\text{C}$ , and aeration is ensured with a continuous supply of bubbled oxygen. Marketed samples of drug and prepared optimized batch is tested ( $n = 3$ ). The drug diffused from the dissolution medium (mucosal side) into the serosal side (absorption compartment) and is analyzed by a validated analytical method at regular time intervals after filtration through a membrane filter of 0.45  $\mu$ m pore size.

#### IV. CURRENT SITUATION AND FUTURE SCOPE

Now a day's pulsatile drug delivery is gaining popularity. The prime advantage in this drug delivery is that drug is released when necessity comes. As a result chance of development of drug resistance which is seen in conventional and sustained release formulations is reduced. Furthermore, some anticancer drugs are very toxic. These drugs provide dangerous issues in conventional and sustained release therapies. Currently several Food and Drug Administration approved chronotherapeutic drugs are available in the market. This therapy is principally applicable wherever sustained action isn't needed and drugs are toxic. Key purpose of this formulation is to seek out circadian rhythm i.e. appropriate indicator which can trigger the discharge of drug from the device. Another point is absence of suitable rhythmic biomaterial which should be biodegradable, biocompatible and reversibly responsive to specific biomarkers in rhythmic manner. Regulatory is another big question. In preapproval phase it's typically difficult to show chronotherapeutic advantage in clinical settings. In post approval phase causal recreational drug abuse along with on a much larger scale, by the criminal diversion of these modified formulations for profit have arisen problems. The FDA has now heavily relied on the development and implementation of risk management programs as a strategy to allow an approval of a drug to go forward while exercising some restrictions. Many researches are going on the pulsatile drug delivery to discover circadian rhythm with suitable device in the world. In future this delivery will be a leading way to deliver therapeutic agents due to its some unique characters like low chance of dose dumping, patient compliance and the above factors.<sup>[67]</sup>

#### CONCLUSION:

Pulsatile drug delivery is one such system that, by delivering a drug at right time, right place, and in right amounts, holds good promises of profit to the patients suffering from chronic issues like arthritis, asthma, hypertension, etc. Extended release

formulations and immediate release formulation aren't efficient in treating the diseases particularly diseases with chronological pathophysiology, for which, pulsatile drug delivery is helpful. The drug is delivering in this system when its actual concentration is required as per chronological need, so pulsatile release systems should be promising in the future.

## REFERENCES

- [1] P. Varuna Panicker , Anu Gopalakrishnan, "Advances in Drug Delivery Systems, World Journal of Pharmacy and Pharmaceutical Sciences,"2014, 3, 255-265..
- [2] Deepika Jain, Richa Raturi, Vikas Jain, Praveen Bansal, and Ranjit Singh, "Recent Technologies in Pulsatile Drug Delivery Systems," 2001, 1, 57-65.
- [3] M.S Neeharika, B. Jeevana Jyothi, "Chorontherapeutics: An Optimizing Approach to Synchronize Drug Delivery with Circadian Rhythm, Journal of Critical Review," 2015 2, 31-40.
- [4] T. Rajendra Mogal, C. Upendra , Galgatte, D. Pravin Chaudhari, "Floating Pulsatile Drug Delivery of Ranitidine Hydrochloride for Nocturnal Acid Breakthrough: Design, Optimization, In Vitro and In Vivo Evaluation, International Journal of Pharmacy and Pharmaceutical Sciences," 2013, 5, 722-727.
- [5] Mahrokh Dadsetan, K. Efuia Taylor, Chun Yong, Zeljko Bajzer, Lichun Lu and Michael Yaszemski .J, " Controlled Release of Doxorubicin From pHResponsive Microgels, Acta Biomater," 2013, 9, 5438–5446.
- [6] SF Hung, CM Hsieh, Chen YC, Lin CM, Sheu MT, " Formulation and Process Optimization of Multiparticulate Pulsatile System Delivered By Osmotic Pressure-Activated Rupturable Membrane, International Journal of Pharmaceutics," 2015, 480, 15-26.
- [7] RS Rohini, "Formulation and Evaluation of Pulsatile Drug Delivery System of Pregabalin, Pharmaceutica Analytica Acta," 2016, 7, 1-4.
- [8] P Neha Singh, Ankita Sharma, Monika Semwal and Meenakshi Ghildiyal , "Formulation and Evaluation of Pulsatile Drug Delivery System Containing Beads of Atorvastatin, World Journal of Pharmacy and Pharmaceutical Sciences," 2018, 7, 816-827.
- [9] B. Senthilnathan, Aviyankavasireddy, Kausalya .J, Suba .V , " Design And Development of Pulsatile Drug Delivery of Glibenclamide Using Pulsincap Technology, International Journal of PharmTech Research," 2012, 4, 1606-1613.
- [10] Sowjanya Battu, Madhavi K, Bhikshapathi DBRN, and K. Abbulu, " Design and Characterization of Valsartan Loaded Press Coated Pulsatile Tablets, Pharmacy and Pharmaceutical Sciences," 2017,6, 49-54.
- [11] Vaishali patil, Dr. S. Chandrasekhara , Dr. C. Nagesh , K. Praveen & S. Rekha , " Pulsatile Drug Delivery System of Terbutaline Sulphate; Using pH Sensitive Polymer, American Journal of Advanced Drug Delivery," 2013,1, 635-650.
- [12] Nitin Saigal, Sanjula Baboota, Alka Ahuja and Javed Ali, "Site Specific Chronotherapeutic Drug Delivery Systems: A Patent Review. Recent Patents on Drug Delivery & Formulation," 2009; 3: 64-70.
- [13] MC Neill , A Rashid , HN Stevens , GB Patent No. GB2230442, 1993.
- [14] S Sarasija, A Hota, "Colon-specific drug delivery systems. Ind. J. Pharm. Sci" 2002, 62(1): 1-8.
- [15] Kinget , Kalala W, Vervoort L, Mooter GV, "Colonic drug targeting. J. Drug Targeting," 1998; 6(2): 129- 149.
- [16] Anamika Singh, Harikesh Dubey, Indu Shukla, Dharmchand P. Singh , " Pulsatile Drug Delivery System: an Approach of Medication according to Circadian Rhythm, Journal of Applied Pharmaceutical Science," 2012, 2, 166-176.
- [17] Crison JR., Siersma PR, Amidon GL, "A novel programmable oral release technology for delivering drugs: human feasibility testing using gamma scintigraphy", Proceed Intern Symp Control Rel. Bioact. Mater ,1996; 23: 51-52.
- [18] Pollock DC, Dong L, Wong P. "A new system to deliver a delayed bolus of liquid drug formulation, Proceed Intern Symp." Control. Rel. Bioact. Mater 2001; 28: 6033.
- [19] Linkwitz A, Magruder JA, Merrill S. "Osmotically Driven Delivery Device with Expandable Orifice for Pulsatile Delivery Effect," US Patent No. 5,318,558, 1994.
- [20] Linkwitz A., Magruder JA, Merrill S. "Osmotically Driven Delivery Device with Expandable Orifice for Pulsatile Delivery Effect," US Patent No. 5,221,278, 1993.
- [21] Balaban SM, Pike JB, Smith JP, Baile CA. "Osmotically Driven Delivery Devices with Pulsatile Effect," US Patent No. 5209746, 1993.
- [22] Magruder PR, Barclay B, Wong PS, Theeuwes F. "Composition Comprising Salbutamol," US Patent No. 4751071, 1988.
- [23] Magruder PR, Barclay B, Wong PS, Theeuwes F." Constant Release System with Pulsed Release," US Patent No. 4777049, 1988.
- [24] Magruder PR., Barclay B, Wong PS, Theeuwes F. Composition Comprising a Therapeutic Agent and a Modulating Agent. US Patent No. 4851229, 1989.
- [25] Gazzaniga A, Iamartino P, Maffione G, Sangalli ME. Oral delayed- release system for colonic specific delivery. Int. J. Pharm. 1994; 2(108): 77-83.
- [26] Gazzaniga A, Sangalli ME, Giordano F. "Oral chronotropic drug delivery systems: achievement of time and/or site specificity.": Eur. J. Biopharm., 1994; 40(4): 246-250.
- [27] Gazzaniga A, Busetto C, Moro L, Crimella T, Sangalli ME, Giordano F. Evaluation of low viscosity HPMC as retarding coating material in the preparation of a time-based oral colon specific delivery system. Proceed Intern Symp Control. Rel. Bioact. Mater 1995; 22: 242-243.
- [28] Poli S, Busetto C, Moro L. Oral Pharmaceutical Composition for Specific Colon Delivery. EP Patent No. 0,572,942, 1993.
- [29] Sangalli ME, Maroni A, Zema L, Busetto C, Giordano F, Gazzaniga A. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J. Control. Rel. 2001; 73: 103-110.

- [30] Maroni A, Sangalli ME, Cerea M, Busetti C, Giordano F, Gazzaniga A. Low viscosity HPMC coating of soft and hard gelatin capsules for delayed and colonic release: preliminary investigations on process parameters and in vitro release performances. *Proceed Int. Control. Rel. Bioact. Mater* 1999; 26: 887-888.
- [31] Patel G. Specialized chronotherapeutic drug delivery systems, [Pharmainfo.net](http://Pharmainfo.net)
- [32] Conte U, Colombo P, Manna A, Gazzaniga A. A new ibuprofen pulsed release oral dosage form. *Drug Dev. Ind. Pharm.* 1989; 15(14- 16): 2583-2596.
- [33] Conte U, Manna A, Colombo P. Tablet for Pharmaceutical Use Able to Release Active Substances at Successive Times, US Patent No. 4,865,849, 1989.
- [34] Conte U, Giunchedi P, Maggi L, Sangalli ME, Gazzaniga A, Colombo P, Manna A. Ibuprofen delayed release dosage forms: a proposal for the preparation of an in vitro/in vivo pulsatile system, *Eur. J. Pharm.* 1992; 38(6): 209-212.
- [35] Krögel I, Bodmeier R. "Floating or pulsatile drug delivery systems based on coated effervescent cores." *Int. J. Pharm* 1999; 187: 175-184.
- [36] Ueda Y, Hata T, Yamaguchi H, Ueda S, Kotani M. "Time Controlled Explosion System and Process for Preparation for the Same," US Patent No. 4,871,549, 1989.
- [37] Ueda Y, Hata T, Yamaguchi H, Kotani M, Ueda S. "Development of a novel drug release system, timecontrolled explosion system (TES)," Part I: concept and design. *J. Drug Targeting* 1994; 2: 35-44.
- [38] Ueda S, Yamaguchi H, Kotani M, Kimura S, Tokunaga Y, Kagayama A, Hata T. "Development of a novel drug release system, time-controlled explosion system (TES), Part II: design of multiparticulate TES and in vitro drug release properties." *Chem. Pharm. Bull.* 1994; 42(2): 359- 363.
- [39] Amidon GL, Leesman GD. "Pulsatile Drug Delivery System," US Patent No. 5,229,131, 1993.
- [40] Bodmeier R, Guo X, Sarabia RE, Skultety P. The influence of buffer species and strength on diltiazem HCl release from beads coated with aqueous cationic polymer dispersions, Eudragit RS, RL 30D, *Pharm. Res.*, 1996; 13 (1): 52-56.
- [41] Beckert TE, Pogarell K, Hack I, Petereit HU. "Pulsed drug release with film coatings" of Eudragit & Mac226; RS 30D. *Proceed Int'l Symp Control. Rel. Bioact. Mater* 1999; 26: 533- 534.
- [42] 56) T. Okano, N. Yui, M. Yokoyama, R. Yoshida. "Advances in Polymeric Systems for Drug Delivery," Gordon and Breach, Yverdon, Switzerland, 1994.
- [43] Y.H. Bae, T. Okano, S.W. Kim. 'On-off' thermocontrol of solute transport. I. Temperature dependence of swelling of N-isopropylacrylamide networks modified with hydrophobic components in water, *Pharm. Res.* 1991; 8 (4): 531-537.
- [44] Y.H. Bae, T. Okano, S.W. Kim. 'On-off' thermocontrol of solute transport. II. Solute release from thermosensitive hydrogels, *Pharm. Res.* 1991; 8 (5): 624-628.
- [45] K. Kataoka, A. Harada, Y. Nagasaki. "Block copolymer micelles for drug delivery: design, characterization and biological significance." *Adv. Drug Deliv. Rev.* 2001; 47: 113-131.
- [46] K. Ishihara, M. Kobayashi, I. Shinohara. "Control of insulin permeation through a polymer membrane with responsive function for glucose," *Makromol. Chem. Rapid Commun.* 1983; 4: 327-331.
- [47] N. Yui, T. Okano, Y. Sakurai. "Inflammation responsive degradation of crosslinked hyaluronic acid gels." *J. Control. Release* 1992; 22: 105-116.
- [48] N. Yui, J. Nihira, T. Okano, Y. Sakurai. "Regulated release of drug microspheres from inflammation responsive degradable matrices of crosslinked hyaluronic acid." *J. Control. Release* 1993; 25: 133- 143.
- [49] B. Berner, S.M. Dinh. "Electronically assisted drug delivery: an overview," *Electronically Controlled Drug Delivery* 1998: 3-7.
- [50] R. Kishi, M. Hara, K. Sawahata, Y. Osada. "Conversion of chemical into mechanical energy by synthetic polymer gels (chemomechanical system). *Polymer Gels — Fundamentals and Biomedical Applications*," Plenum Press, New York, 1991, pp. 205-220.
- [51] I.C. Kwon, Y.H. Bae, T. Okano, B. Berner, S.W. Kim. "Stimuli sensitive polymers for drug delivery systems," *Makro mol. Chem. Macromol. Symp* 1990; 33: 265-277.
- [52] Saslawski O, Weigarten C, Benoit JP, et al. "Magnetically responsive microspheres for the pulsed delivery of insulin." *Life Sci.* 1988; 42 (16): 1521-1528.
- [53] Miyazaki S, Yokouchi C and Takada M. "External control of drug release: controlled release of insulin from a hydrophilic polymer implant by ultrasound irradiation in diabetic rats." *J. Pharm. Pharmacol* 1988; 40: 716-717.
- [54] Mathiowitz E, Raziell A, Cohen MD, et al. "Novel deciccants Based on Designed Polymeric Blends." *J. Appl.Polym. Sci.* 1981; 26: 809-822.
- [55] Dashevsky A and Mohamad A. *Int. J. pharm.* 2006; 318: 124-131.
- [56] Sharma S and Pawar A. "Low Density multiparticulate system for pulsatile release of meloxicam." *Int. J. pharm.* 2006; 313(1): 150-158.
- [57] Lachman "The theory and Practice of Industrial Pharmacy" 3rd edition.
- [58] Ahmad Mohamad, Andrei Dashevsky. "pHIndependent pulsatile drug delivery system based on hard gelatin capsules and coated with aqueous dispersion Aquacoat ECD." *European Journal of Pharmaceutics and Biopharmaceutics* 2006; 64: 173-179
- [59] Harkness JAL, Richter MB, Panayi GS. "Circadian variation in disease activity in rheumatoid arthritis." *British Medical J.* 1982; 284: 551-554.
- [60] Stevens HNE, Wilson CG, Welling PG, et al. "Evaluation of pulscinap to provide regional delivery of dofetilide to the human G.I. tract." *Int. J. pharm* 2002; 236 :27-34.

- [61] Dasharath M Patel, Rushiraj H Jani, Chhagan N Patel. "Design and evaluation of colon targeted modified pulsincap delivery of 5-fluorouracil according to circadian rhythm." *International Journal of Pharmaceutical Investigation* 2011; 1(3): 172-181.
- [62] Santanu Ghosh, BB Barik. "A comparative study of the pharmacokinetics of conventional and sustained-release tablet formulations of aceclofenac in healthy male subjects, *Tropical Journal of Pharmaceutical Research*", 2010; 9 (4): 395-399.
- [63] Maha Abd El-Hamid Marzouk, Alaa El-Din Ali Kassem, Ahmed Mahmoud Samy, Riham Ibrahim Amer. "In-vitro release, Thermodynamics and Pharmacodynamic Studies of Aceclofenac Transdermal Eudragit Patches." *Drug Invention Today* 2009; 1(1): 16-22.
- [64] Kale VV, Kasliwal RH, Avari JG. "Attempt to design continuous dissolution-absorption system using everted intestine segment for in vitro absorption studies of slow drug release formulations. *Dissolution Technologies*" 2007; 14: 31-36.
- [65] Mariappan TT, Singh S. "Evidence of efflux mediated and saturable absorption of rifampicin in rat intestine using the ligated loop and everted gut sac techniques." *Mol Pharm.* 2004; 1: 363-367.
- [66] Asim Sattwa Mandal, Nikhil Biswas, Kazi Masud Karim, Arijit Guha, Sugata Chatterjee, Mamata Behera, Ketousetuo Kuotsu, "Drug delivery system based on chronobiology—A review. *Journal of Controlled Release*," 2010; 10.

